Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
89bio (ETNB) Stock Price & Analysis
719 Followers
ETNB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.58 - $22.93
Previous Close$9.03
Volume228.46K
Average Volume (3M)1.13M
Market Cap
$867.50M
Enterprise Value$632.82M
Total Cash (Recent Filing)$251.93M
Total Debt (Recent Filing)$24.87M
Price to Earnings (P/E)-4.5
Beta0.74
Next Earnings
Aug 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding93,501,210
10 Day Avg. Volume667,875
30 Day Avg. Volume1,134,562
Standard Deviation0.26
R-Squared0.05
Alpha-0.00155
Financial Highlights & Ratios
Price to Book (P/B)1.63
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.99
Forecast
1Y Price Target
$29.80Price Target Upside227.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
89bio News
PremiumStock Analysis & Ideas
‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks
PremiumCompany Announcements
89bio Enhances Board with Biopharma Veteran Martin Babler
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesConsistent and robust effects in F2-F3 NASH patients demonstrate pegozafermin's potential efficacy, with sustained improvements in liver biomarkers.
Drug Development And Regulatory MilestonePegozafermin receives PRIME status from EMA for treatment of MASH, reflecting confidence in its potential to address unmet medical needs.
Market PotentialWith a projected peak sales forecast of $6.5 billion for pegozafermin, the commercial opportunity for MASH treatments is substantial.
Bears Say
Clinical And Regulatory RisksRisks include potential clinical trial failure and challenges in securing regulatory approvals.
Drug Acceptance ConcernsConcerns regarding a reduction in bone mineral density specific to EFX could pose challenges in its acceptance and future trial results.
Market ChallengesNear-term commercial challenges for competitors in the MASH market may impact 89Bio's stock, but the long-term unmet need remains substantial.
---
Ownership Overview
22.95% Insiders
16.39% Mutual Funds
14.54% Other Institutional Investors
46.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ETNB FAQ
What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $6.58 and its highest was $22.93 in the past 12 months.
What is 89bio’s market cap?
Currently, no data Available
When is 89bio’s upcoming earnings report date?
89bio’s upcoming earnings report date is Aug 08, 2024 which is in 90 days.
How were 89bio’s earnings last quarter?
Currently, no data Available
Is 89bio overvalued?
According to Wall Street analysts 89bio’s price is currently Undervalued.
Does 89bio pay dividends?
89bio does not currently pay dividends.
What is 89bio’s EPS estimate?
89bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 89bio have?
89bio has 95,224,724 shares outstanding.
What happened to 89bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 89bio?
Among the largest hedge funds holding 89bio’s share is RA Capital Management. It holds 89bio’s shares valued at 128M.
---
89bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.80 (227.11% Upside)
$29.80 (227.11% Upside)
Blogger Sentiment
Bullish
ETNB Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 509.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.10%
12-Months-Change
Fundamentals
Return on Equity
-41.33%
Trailing 12-Months
Asset Growth
202.95%
Trailing 12-Months
Company Description
89bio
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
---
ETNB Stock 12 Month Forecast
Average Price Target
$29.80
▲(227.11% Upside)
Technical Analysis
Best Analysts Covering ETNB
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+88.06%
reiterated a buy rating 2 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +88.06% per trade.
---